Seelos Therapeutics

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York.

Dr. Mehra says since listing on the exchange in January, the small company has achieved an 'incredible feat' by laying the groundwork to potentially be engaging in a pivotal study to treat orphan diseases and proof-of-concept studies to prevent and treat suicide and depression. 

Quick facts: Seelos Therapeutics

Price: $1.79

Market: NASDAQ
Market Cap: $40.01 m

More on this story


Redx Pharma gets green light to increase dose in lead cancer drug trial

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

2 days, 3 hours ago

2 min read